481 related articles for article (PubMed ID: 31807935)
1. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
[TBL] [Abstract][Full Text] [Related]
3. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Cheah CY; Opat S; Trotman J; Marlton P
Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
[TBL] [Abstract][Full Text] [Related]
4. Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.
Joshi M; Sheikh H; Abbi K; Long S; Sharma K; Tulchinsky M; Epner E
Ther Adv Hematol; 2012 Oct; 3(5):275-90. PubMed ID: 23616915
[TBL] [Abstract][Full Text] [Related]
5. Contemporary management of nodal and primary splenic marginal zone lymphoma.
Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH
Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ; Feng L; Strati P; Lee HJ; Hagemeister FB; Westin JR; Samaniego F; Marques-Piubelli ML; Vega Vazquez F; Parra Cuentas ER; Solis-Soto LM; Ma W; Wang J; Claret L; Averill B; Ibanez K; Fayad LE; Flowers CR; Green MR; Davis RE; Neelapu SS; Fowler NH; Nastoupil LJ
Cancer; 2024 Mar; 130(6):876-885. PubMed ID: 37985359
[TBL] [Abstract][Full Text] [Related]
7. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
8. [Current management of marginal zone lymphomas].
Bonnet C; Lejeune M; Van Kemseke C; Bron D; Beguin Y
Rev Med Suisse; 2015 Aug; 11(483):1549-56. PubMed ID: 26502581
[TBL] [Abstract][Full Text] [Related]
9. Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Leslie LA
Curr Treat Options Oncol; 2021 Oct; 22(12):111. PubMed ID: 34694508
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.
Ollila TA; Olszewski AJ
Cancer Manag Res; 2021; 13():3935-3952. PubMed ID: 34017197
[TBL] [Abstract][Full Text] [Related]
11. Transformation of marginal zone lymphoma (and association with other lymphomas).
Casulo C; Friedberg J
Best Pract Res Clin Haematol; 2017; 30(1-2):131-138. PubMed ID: 28288708
[TBL] [Abstract][Full Text] [Related]
12. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
13. Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.
Ayyappan S; William BM
Curr Oncol Rep; 2018 Mar; 20(4):33. PubMed ID: 29572581
[TBL] [Abstract][Full Text] [Related]
14. Marginal zone B-cell lymphomas.
Sagaert X; Tousseyn T
Discov Med; 2010 Jul; 10(50):79-86. PubMed ID: 20670602
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G; Bazarbachi A; El-Cheikh J
Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
[TBL] [Abstract][Full Text] [Related]
16. Management of Marginal Zone Lymphoma: A Canadian Perspective.
Peters A; Keating MM; Nikonova A; Doucette S; Prica A
Curr Oncol; 2023 Feb; 30(2):1745-1759. PubMed ID: 36826096
[TBL] [Abstract][Full Text] [Related]
17. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites.
Kuper-Hommel MJ; van de Schans SA; Vreugdenhil G; van Krieken JH; Coebergh JW
Leuk Lymphoma; 2013 Sep; 54(9):1891-7. PubMed ID: 23302044
[TBL] [Abstract][Full Text] [Related]
18. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
[TBL] [Abstract][Full Text] [Related]
19. Current Treatments in Marginal Zone Lymphoma.
Alderuccio JP; Kahl BS
Oncology (Williston Park); 2022 Apr; 36(4):206-215. PubMed ID: 35436062
[TBL] [Abstract][Full Text] [Related]
20. Marginal-zone lymphoma.
Ferreri AJ; Zucca E
Crit Rev Oncol Hematol; 2007 Sep; 63(3):245-56. PubMed ID: 17583528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
